NO20052170L - Heparin-derived polysaccharide mixtures, their preparation and pharmaceutical compositions containing the same - Google Patents

Heparin-derived polysaccharide mixtures, their preparation and pharmaceutical compositions containing the same

Info

Publication number
NO20052170L
NO20052170L NO20052170A NO20052170A NO20052170L NO 20052170 L NO20052170 L NO 20052170L NO 20052170 A NO20052170 A NO 20052170A NO 20052170 A NO20052170 A NO 20052170A NO 20052170 L NO20052170 L NO 20052170L
Authority
NO
Norway
Prior art keywords
heparin
activity
hexasaccharide
preparation
same
Prior art date
Application number
NO20052170A
Other languages
Norwegian (no)
Other versions
NO20052170D0 (en
Inventor
Pierre Mourier
Christian Viskov
Luc Grondard
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20052170D0 publication Critical patent/NO20052170D0/en
Publication of NO20052170L publication Critical patent/NO20052170L/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078Degradation products
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

New mixtures (A) of heparin-derived sulfated polysaccharides have average molecular weight 1500-3000, anti-Xa activity 120-200 IU/mg, anti-IIa activity 0-10 IU/mg and ratio of anti-Xa to anti-IIa activity more than 30; comprise 2-26 saccharide units; have a 4,5- unsaturated uronic acid 2-O-sulfate unit at one terminal; contain a specific hexasaccharide moiety designated DELTAIIa-IIs-Is hexasaccharide; and are in alkali(ne earth) metal salt form. New mixtures (A) of sulfated polysaccharides have the general structure of the constitutive polysaccharides of heparin, an average molecular weight of 1500-3000, an anti-Xa activity of 120-200 IU/mg, an anti-IIa activity of 0-10 IU/mg and a ratio of anti-Xa to anti-IIa activity of more than 30. The constitutive oligosaccharides of (A) comprise 2-26 saccharide units; have a 4,5- unsaturated uronic acid 2-O-sulfate unit at one terminal; contain a hexasaccharide moiety of formula (I) (designated DELTAIIa-IIs-Is hexasaccharide) and are in alkali(ne earth) metal salt form. An Independent claim is included for the preparation of (A).
NO20052170A 2002-10-10 2005-05-03 Heparin-derived polysaccharide mixtures, their preparation and pharmaceutical compositions containing the same NO20052170L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0212584A FR2845686B1 (en) 2002-10-10 2002-10-10 MIXTURES OF HEPARIN-DERIVED POLYSACCHARIDES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PCT/FR2003/002960 WO2004033503A1 (en) 2002-10-10 2003-10-08 Heparin-derived polysaccharide mixtures, preparation thereof and pharmaceutical compositions containing same

Publications (2)

Publication Number Publication Date
NO20052170D0 NO20052170D0 (en) 2005-05-03
NO20052170L true NO20052170L (en) 2005-07-07

Family

ID=32039597

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052170A NO20052170L (en) 2002-10-10 2005-05-03 Heparin-derived polysaccharide mixtures, their preparation and pharmaceutical compositions containing the same

Country Status (35)

Country Link
EP (1) EP1556414B1 (en)
JP (2) JP5021898B2 (en)
CN (6) CN101812139A (en)
AT (1) ATE548393T1 (en)
AU (1) AU2003300161B2 (en)
BR (1) BR0315149A (en)
CA (1) CA2501546C (en)
CY (1) CY1112808T1 (en)
DK (1) DK1556414T3 (en)
EC (1) ECSP055722A (en)
ES (1) ES2383597T3 (en)
FR (1) FR2845686B1 (en)
GT (1) GT200300181A (en)
HN (1) HN2003000312A (en)
IL (1) IL167868A (en)
MA (1) MA27398A1 (en)
MX (1) MXPA05003321A (en)
MY (1) MY142376A (en)
NI (1) NI200300087A (en)
NO (1) NO20052170L (en)
NZ (1) NZ539229A (en)
OA (1) OA12940A (en)
PA (1) PA8584201A1 (en)
PE (1) PE20040507A1 (en)
PT (1) PT1556414E (en)
RS (1) RS20050274A (en)
RU (1) RU2332424C2 (en)
SI (1) SI1556414T1 (en)
SV (1) SV2004001626A (en)
TN (1) TNSN05101A1 (en)
TW (1) TWI332010B (en)
UA (1) UA81925C2 (en)
UY (1) UY28016A1 (en)
WO (1) WO2004033503A1 (en)
ZA (1) ZA200502787B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2845686B1 (en) * 2002-10-10 2013-08-30 Aventis Pharma Sa MIXTURES OF HEPARIN-DERIVED POLYSACCHARIDES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2857971B1 (en) * 2003-07-24 2005-08-26 Aventis Pharma Sa MIXTURES OF HEPARIN DERIVED OLIGOSACCHARIDES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AU2007267561B2 (en) * 2006-05-25 2012-05-17 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
WO2008068854A1 (en) 2006-12-05 2008-06-12 Glycoscience Laboratories, Inc. Therapeutic agent for degenerative arthritis
ES2610240T3 (en) * 2009-02-02 2017-04-26 Otsuka Chemical Co., Ltd. Low molecular weight polysulfated hyaluronic acid derivative and medicine containing it
EP2233145A1 (en) 2009-03-19 2010-09-29 Sanofi-Aventis A dose of AVE5026 for the treatment of venous thromboembolism in patients with severe renal impairment
EP2399592A1 (en) 2010-06-25 2011-12-28 Aventis Pharma S.A. Semuloparin for use as an antithrombotic treatment in hip replacement surgery with improved safety in terms of clinically relevant bleedings and major bleedings
EP2399590A1 (en) 2010-06-25 2011-12-28 Aventis Pharma S.A. Semuloparin for the prevention of a mortality and/or morbidity event in a patient undergoing major orthopaedic surgery
EP2399591A1 (en) 2010-06-25 2011-12-28 Aventis Pharma S.A. Semuloparin for the extended prevention of a mortality and/or morbidity event in a patient having undergone hip fracture surgery
EP2399593A1 (en) 2010-06-28 2011-12-28 Aventis Pharma S.A. Semuloparin for use as an antithrombotic treatment in orthopaedic surgery with improved benefit-risk profile
JP2012046511A (en) * 2010-07-30 2012-03-08 Otsuka Chem Co Ltd Pharmaceutical agent containing low molecular weight polysulfated hyaluronic acid derivative
CA3020369C (en) * 2010-09-14 2019-11-26 University Of Miyazaki High purity heparin and production method therefor
EP2446891A1 (en) 2010-10-28 2012-05-02 Aventis Pharma S.A. Semuloparin for use as an antithrombotic treatment in major abdominal surgery with improved safety in terms of clinically relevant bleedings and major bleedings
WO2012055843A1 (en) 2010-10-28 2012-05-03 Aventis Pharma S.A. Semuloparin for the prevention of major venous thromboembolism in a patient undergoing major abdominal surgery
WO2012072799A1 (en) 2010-12-02 2012-06-07 Aventis Pharma S.A. New methods for the in vitro measurement of the biological activity of an ultra low molecular weight heparin sample
AR085961A1 (en) 2011-04-11 2013-11-06 Sanofi Sa POLISACARIDS THAT HAVE TWO SITES OF UNION TO ANTHROMBIN III, METHOD TO PREPARE THEM AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
EP2548561A1 (en) 2011-07-22 2013-01-23 Aventis Pharma S.A. Semuloparin for improving the survival of patients with locally advanced cancer
WO2013044793A1 (en) * 2011-09-26 2013-04-04 Xu Meiying High-purity heparin benzyl ester salt, preparation method therefor and application thereof
CN102633908A (en) * 2012-05-02 2012-08-15 雷晓刚 Method for preparing high-quality LMW (low molecular weight) heparins
ES2445494B1 (en) * 2012-08-02 2015-03-06 Rovi Lab Farmaceut Sa Procedure for obtaining low and very low molecular weight heparins
US9873712B2 (en) * 2014-10-03 2018-01-23 Amphastar Pharmaceuticals, Inc. Method of purifying idraparinux sodium
EP3398971A4 (en) * 2015-12-30 2019-09-25 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Sulfated heparin oligosaccharide and preparation method and application thereof
CZ308106B6 (en) * 2016-06-27 2020-01-08 Contipro A.S. Unsaturated derivatives of polysaccharides, preparing and using them
CN110917208B (en) * 2019-12-27 2021-02-12 浙江医院 Application of sulfated mannoglucuronhexaose in preventing and treating atherosclerosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61201A (en) * 1979-10-05 1984-09-30 Choay Sa Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them
FR2482611B1 (en) 1980-05-14 1986-03-07 Pharmindustrie NOVEL SULFATED POLYSACCHARIDES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
FR2504928A1 (en) * 1981-04-29 1982-11-05 Choay Sa SHORT CHAIN OLIGOSACCHARIDES HAVING BIOLOGICAL PROPERTIES, PREPARATION THEREOF AND APPLICATIONS THEREOF AS MEDICAMENTS
FR2584606A1 (en) * 1985-07-12 1987-01-16 Dropic USE OF POLY- AND OLIGOSACCHARIDES FOR THE PRODUCTION OF ACTIVE MEDICAMENTS IN THE PATHOLOGIES OF CONNECTIVE TISSUE
FR2584728B1 (en) * 1985-07-12 1987-11-20 Choay Sa PROCESS FOR THE SULFATION OF GLYCOSAMINOGLYCANS AND THEIR FRAGMENTS
ES2161615B1 (en) * 1999-07-23 2003-03-16 Rovi Lab Farmaceut Sa COMPOSITIONS OF HEPARINS OF VERY LOW MOLECULAR WEIGHT.
JP4897991B2 (en) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ Ultra low molecular weight heparin composition
FR2807043B1 (en) * 2000-03-28 2002-11-22 Aventis Pharma Sa PHARMACEUTICAL COMPOSITION CONTAINING OLIGOSACCHARIDES, NEW OLIGOSACCHARIDES AND THEIR PREPARATION
FR2811992B1 (en) * 2000-07-21 2003-07-04 Aventis Pharma Sa MIXTURES OF HEPARIN-DERIVED POLYSACCHARIDES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2845686B1 (en) * 2002-10-10 2013-08-30 Aventis Pharma Sa MIXTURES OF HEPARIN-DERIVED POLYSACCHARIDES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Also Published As

Publication number Publication date
DK1556414T3 (en) 2012-06-25
JP5389140B2 (en) 2014-01-15
AU2003300161B2 (en) 2009-08-27
CN101812139A (en) 2010-08-25
ZA200502787B (en) 2005-10-18
NI200300087A (en) 2012-02-02
CN101812189A (en) 2010-08-25
IL167868A (en) 2010-05-31
EP1556414A1 (en) 2005-07-27
CN101810637A (en) 2010-08-25
NZ539229A (en) 2008-03-28
CN101817940A (en) 2010-09-01
UA81925C2 (en) 2008-02-25
MA27398A1 (en) 2005-06-01
GT200300181A (en) 2004-03-24
RS20050274A (en) 2007-06-04
WO2004033503A1 (en) 2004-04-22
PT1556414E (en) 2012-05-21
NO20052170D0 (en) 2005-05-03
ATE548393T1 (en) 2012-03-15
BR0315149A (en) 2005-08-16
CN1798771A (en) 2006-07-05
CN101812190A (en) 2010-08-25
ES2383597T3 (en) 2012-06-22
FR2845686A1 (en) 2004-04-16
ECSP055722A (en) 2005-07-06
SV2004001626A (en) 2004-03-08
RU2332424C2 (en) 2008-08-27
RU2005113987A (en) 2006-01-27
TWI332010B (en) 2010-10-21
MY142376A (en) 2010-11-30
PE20040507A1 (en) 2004-10-13
MXPA05003321A (en) 2005-07-05
CY1112808T1 (en) 2016-02-10
TW200418882A (en) 2004-10-01
JP2012051926A (en) 2012-03-15
UY28016A1 (en) 2004-04-30
OA12940A (en) 2006-10-13
TNSN05101A1 (en) 2007-05-14
JP5021898B2 (en) 2012-09-12
AU2003300161A1 (en) 2004-05-04
CA2501546C (en) 2012-04-03
PA8584201A1 (en) 2004-08-31
FR2845686B1 (en) 2013-08-30
JP2006517185A (en) 2006-07-20
EP1556414B1 (en) 2012-03-07
SI1556414T1 (en) 2012-06-29
HN2003000312A (en) 2005-10-20
CA2501546A1 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
NO20052170D0 (en) Heparin-derived polysaccharide mixtures, their preparation and pharmaceutical compositions containing the same
US4791195A (en) Novel oligosaccharides having pharmacological properties by depolymerization of heparin
Cheng et al. Solution NMR spectroscopy of food polysaccharides
Nahain et al. Heparin mimetics with anticoagulant activity
Mestechkina et al. Sulfated polysaccharides and their anticoagulant activity: A review
HRP20180124T1 (en) Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use
Nishino et al. An anticoagulant fucoidan from the brown seaweed Ecklonia kurome
HUP0204196A2 (en) Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect, process for their preparation and pharmaceutical compositions containing them
EP0970130B1 (en) Glycosaminoglycans having high antithrombotic activity
SI2794667T1 (en) Low anticoagulant heparins
AR029865A1 (en) MIXTURES OF SULFATED POLYSACARIDS DERIVED FROM HEPARINE, ITS PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
NZ333721A (en) Pharmaceutically acceptable synthetic polysaccharides
IT1282994B1 (en) DERIVATIVES OF THE POLYSACCHARIDE K5 HAVING HIGH ANTI-COAGULANT ACTIVITY
WO2020133362A1 (en) Kit for caring for the skin
WO1998040081A1 (en) Sulfated oligosaccharides having anticoagulant/antithrombotic activity
HRP20230820T1 (en) Heparan sulfate having high 3-o-sulfation rate of glucosamine residues
US5849721A (en) Sulfated polysaccharides obtained from heparin, preparation process, pharmaceutical composition and use thereof
TW200704403A (en) Dilution resistant viscoelastic compositions
JP2004210715A5 (en)
DK0986580T3 (en) Oligosaccharide mixtures with antithrombotic activity
PE20050246A1 (en) HEPARIN-DERIVED OLIGOSACCHARD MIXTURES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
Franz et al. Novel pharmaceutical applications of polysaccharides
ATE388169T1 (en) LOW MOLECULAR POLYSACCHARIDES WITH ANTITHROMBOTIC EFFECT
AU721179B2 (en) Sulfated oligosaccharides having anticoagulant/antithrombotic activity
TH68733A (en) Mixtures of polysaccharide derived from heparin Pharmaceutical preparations and mixtures containing them

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application